Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices
BioAgilytix has been fortunate enough to have several of our team members participate as co-authors on all three AAPS white papers in the series on…
A Dose of Pharma and Biotech News: December 12, 2019
With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest…
Bioanalytical Testing Under GMP: Optimizing Cell-Based Potency Assays
Cell-based bioassays are expected by health agencies as one of the release specification methods for potency assessments in the drug development process. We take a…
BioAgilytix Team Q&A: Meet Tatjana Ackermann, Quality Assurance Auditor
We strive to foster an environment where our team members can continually grow within their role and within the company – not only upwards, but…
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway in Boston
The first in-human in vivo clinical trial using CRISPR-Cas9 is now open for enrollment; we take a closer look at this genome editing technology to…
BioAgilytix Team Q&A: Meet Janett Schwarz, Principal Investigator at BioAgilytix
In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our…
Event Line-Up: The Bioanalytical Industry Forums We’ll Be at This Fall
We're looking forward to participating in several upcoming bioanalytical conferences and events this fall, ranging from small-circle workshops to global, world-renowned industry forums.
BioAgilytix Team Q&A: Meet Eric Nesbit, Bioanalytical Project Manager/Scientist III
In this Q&A session we talk with Eric Nesbit, Bioanalytical Project Manager/Scientist III at BioAgilytix, to learn more about what led him to leave his…
Meet Jelle Hempenius, Business Development Director, Europe
Did you know that BioAgilytix’s ‘deep bench’ extends beyond those we have working in the lab? Many individuals in our operational departments, from business development…
Gene Therapy Trends: Conditional Approval of Zynteglo Brings Ex Vivo Gene Therapy Into Focus
The recent approval of Zynteglo further builds credibility to the specific and emerging class of cell therapies engineered via “ex vivo” gene therapy. We explain…